Jazz new stomach cancer drug extends survival by 7 months but causes severe side effects in 25% of patients. Ziihera-only combination failed to achieve statistical significance for overall survival at first analysis.
Zymeworks jumps 31% and Jazz Pharmaceuticals rises 26% after announcing successful Phase 3 trial results for Ziihera cancer treatment targeting stomach and esophageal cancers.
The FDA approved the Zepzelca/Tecentriq drug combo as a maintenance treatment for advanced small cell lung cancer.
Amneal Pharmaceuticals receives FDA approval for its generic sodium oxybate, offering a more accessible and cost-effective treatment for narcolepsy's excessive sleepiness and cataplexy in patients 7+.
